首页> 外文期刊>Breast cancer research and treatment. >Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.
【24h】

Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.

机译:乳腺癌中干扰素调节因子-1基因位点的杂合性经常丢失。

获取原文
获取原文并翻译 | 示例
           

摘要

The interferon regulatory factor-1 (IRF1) gene, localized on chromosome 5q31.1, is mutated or rearranged in several cancers including some hematopoietic and gastric cancers. However, whether loss of IRF1 occurs in sporadic breast cancer is unknown. Loss of 5q12-31 is reported in 11% of sporadic breast cancers, and high-resolution array-CGH studies have shown loss at 5q31.1 in 50% of breast cancers with a mutated BRCA1 gene. Functionally, overexpression of IRF1 reduces, and a dominant negative IRF1 construct increases, tumorigenesis of human breast cancer xenografts. Taken together, these observations indicate that the IRF1 gene may play a potentially important role as a breast cancer tumor suppressor gene. In this study, we investigated allelic loss of the IRF1 gene in breast tumor specimens from 52 women with invasive breast cancer using an IRF1 intragenic dinucleotide polymorphic marker. Thirty-seven cases were informative. LOH at the IRF1 locus was detected in 32% of these informative cases (12/37). There was a significant association between IRF1 loss and both older age (P = 0.0167) and earlier stage (Stages 1 and 2) (P = 0.0165). To assess the association of IRF1 mRNA expression with clinical outcomes in breast cancer, we studied data from two published gene expression microarray datasets. In breast cancer patients, low IRF1 mRNA expression is strongly correlated with both risk of recurrence (OR = 3.00; P = 0.003; n = 273 cases) and risk of death (OR = 4.18; P = 0.004; n = 191 cases). Our findings strongly imply a tumor suppressor role for the IRF1 gene in breast cancer.
机译:干扰素调节因子1(IRF1)基因位于5q31.1号染色体上,在几种癌症(包括某些造血和胃癌)中发生突变或重新排列。但是,IRF1的丢失是否在散发性乳腺癌中发生尚不清楚。据报道,在11%的散发性乳腺癌中5q12-31缺失,高分辨率阵列CGH研究显示,在50%的BRCA1基因突变的乳腺癌中,在5q31.1缺失。从功能上讲,IRF1的过表达减少了,而显性负IRF1的构建体增加了,人类乳腺癌异种移植物的肿瘤发生。综上所述,这些观察结果表明IRF1基因可能作为乳腺癌抑癌基因发挥潜在的重要作用。在这项研究中,我们使用IRF1基因内双核苷酸多态性标记物调查了52例浸润性乳腺癌女性乳腺肿瘤标本中IRF1基因的等位基因缺失。 37例提供了信息。在这些信息丰富的病例中,有32%检测到IRF1基因座处的LOH(12/37)。 IRF1丢失与年龄较大(P = 0.0167)和早期(阶段1和2)(P = 0.0165)之间存在显着关联。为了评估乳腺癌中IRF1 mRNA表达与临床结局的关联,我们研究了来自两个已发表的基因表达微阵列数据集的数据。在乳腺癌患者中,低IRF1 mRNA表达与复发风险(OR = 3.00; P = 0.003; n = 273例)和死亡风险(OR = 4.18; P = 0.004; n = 191例)密切相关。我们的发现强烈暗示IRF1基因在乳腺癌中具有抑癌作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号